Authors
Latest:
Biosimilar Uptake in Oncology Faces Many HurdlesCarina Dolan, PharmD, BCOP, discusses the factors that impact the successful uptake of biosimilars in the practice of oncology.
Latest:
Resection and Reconstruction of a Solitary Sternal Metastasis After Mastectomy for Breast Cancer: A Case Report and Review of the LiteratureIn May 2005, a 25-year-old female presented to her primary care physician complaining of a newly palpable breast mass that had grown to several centimeters over the course of a few months.
Latest:
Dr. Olsson on Differences Between LHRH Agonists and Antagonists in Prostate CancerCarl Olsson, MD, Integrated Medical Professionals, compares the efficacy of LHRH agonists with antagonists, which are commonly used to treat patients with prostate cancer.
Latest:
Dr. Casulo on Predicting Outcomes in Follicular LymphomaCarla Casulo, MD, discusses several different factors that can help predict outcomes in patients with follicular lymphoma.
Latest:
Glycans Emerge as Promising Biomarkers for Early Detection of Many Cancer TypesFor many years, we in the medical and research communities have tried to use proteins and DNA fragments as disease markers to find cancer early.
Latest:
Dr. Arteaga on PI3K Pathway InhibitorsCarlos Arteaga, MD, assistant director, Clinical Research, director, Breast Cancer program, Vanderbilt-Ingram Cancer Center, discusses the PI3K pathway and the role of therapeutic inhibitors in reducing the progression of breast cancer.
Latest:
Dr Arteaga on CDK4/6 Inhibitor Resistance in ER+ Breast CancerCarlos Arteaga, MD, discusses the resistance to CDK4/6 inhibitors in estrogen receptor–positive breast cancer.
Latest:
Dr. Becerra Discusses Dosing Strategies in CRCCarlos Becerra, MD, medical oncologist, Texas Oncology, discusses dosing strategies in the treatment of patients with colorectal cancer.
Latest:
Dr. Vargas on Research With Proton Therapy in Prostate CancerCarlos E. Vargas, MD, discusses research with proton therapy in prostate cancer.
Latest:
Dr. Barcenas on Colestipol in Management of Neratinib Side Effects in HER2+ Breast CancerCarlos Barcenas, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses managing neratinib-related side effects with colestipol (Colestid).
Latest:
Dr. Arteaga Discusses the CALGB 40603 TrialCarlos L. Arteaga, MD,discusses the CALGB 40603 trial, a neoadjuvant triple-negative breast cancer trial.
Latest:
Dr. Bachier on the Potential Benefits of Liso-Cel in DLBCLCarlos R. Bachier, MD, discusses the investigational CAR T-cell therapy lisocabtagene maraleucel in diffuse large B-cell lymphoma.
Latest:
Carlton Brown Describes the ONS Social Media EffortsOncology Nursing Society President Carlton Brown Describes the ONS Social Media Efforts
Latest:
ONS President Carl Brown on Key Messages of the CongressCarlton Brown Describes Key Messages of the ONS Congress
Latest:
When to Consider Referral to a Genetic Counselor for Lesser Known Cancer SyndromesExperts discuss the clinical features, gene function, and medical management recommendations for six hereditary cancer syndromes.
Latest:
Dr. Nucera Discusses the Role of RNA in Thyroid CancerCarmelo Nucera, MD, PhD, endocrinologist, assistant professor, Harvard Medical School, Division of Experimental Pathology, Beth Israel Deaconesss Medical Center, Boston, discusses the role of RNA in thyroid cancer
Latest:
Dr. Aghajanian on Ovarian Cancer Trial EndpointsCarol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.
Latest:
Carol Bush on Navigators and Healthcare ReformCarol Bush, BS, RN, Patient Navigator, Midwest Cancer Alliance, The University of Kansas Cancer Center, discusses the role of oncology nurse navigators in healthcare reform.
Latest:
The Benefits for Nurses of Using Psychosocial Cancer Registry DataRegistries, large databases of patient information collected in a systematic, standardized fashion, most often focus on biologic measures, such as pathology, radiology, and laboratory results, to track incidence and prevalence of disease as well as causative factors.
Latest:
Carol Bush on the MCA Telehealth NetworkCarol Bush, BS, RN, from the The University of Kansas Cancer Center, on the Midwest Cancer Alliance Telehealth Network
Latest:
Carol Tringali on Closing the Gaps in Psychosocial CareCarol Tringali on Closing the Gaps in Psychosocial Care
Latest:
Dr. Atanasio on Ibrutinib and Obinuzutumab Combination in CLL/SLLCarolina Moreno Atanasio, MD, University of Barcelona, discusses an ongoing phase III study comparing ibrutinib and obinutuzumab with chlorambucil and obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Latest:
Dr. Robert on Potential of Dabrafenib/Trametinib in Melanoma Brain MetastasesCaroline Robert, MD, PhD, head of the Dermatology Unit at the Institut Gustave-Roussey, co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University, explains why patients with melanoma and brain metastases were excluded from a trial evaluating the efficacy of dabrafenib plus trametinib.
